Fundz

Karolinska Development's Portfolio Company Anacardio Raises Sek 33 Million To Progress Clinical Development Of A Novel Therapy For Heart Failure

PRIVATEFeb 03, 2022

Amount Raised

SEK33 Million

Round Type

Seed

StockholmSoftwareHealth Care

Description

STOCKHOLM, SWEDEN February 3, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed a fundraising of SEK 33 million comprised of a convertible loan. Karolinska Development participated in this important funding, which enables AnaCardio to proceed with the clinical development plans for the company’s lead asset AC01.

Who to call at AnaCardio, and when

A new round usually means AnaCardio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day AnaCardio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at AnaCardio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at AnaCardio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

AnaCardio

Location

Stockholm, Stockholm County, Sweden

About

AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is planned to enter phase 2 clinical development in heart failure patients in 2022.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment AnaCardio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsPatrik S., CEO hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for AnaCardio's next move

See what Strategic adds

AnaCardio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.